Sawari Ventures

Sawari Ventures is a venture capital firm based in Cairo, Egypt, established in 2010. The firm focuses on investing in early and growth-stage technology companies across North Africa, with a particular emphasis on Egypt, Tunisia, and Morocco. Their investment sectors include fintech, edtech, healthtech, deeptech, logistics, e-commerce, consumer internet, cleantech, ICT, hardware, education, healthcare, transportation & storage, software-as-a-service, and converged services. Sawari Ventures operates two main funds: the North Africa Fund I, a $50 million fund that supports growth-stage businesses primarily in Egypt, and the Egypt Fund I, which targets domestic opportunities and often co-invests with international partners. The firm typically invests between $100,000 and $5 million in seed, Series A, and Series B+ rounds, emphasizing scalable, technology-driven businesses that address regional challenges. To date, Sawari Ventures has invested in 19 companies and 2 seed stage vehicles, collaborating with development finance institutions and regional investors to support high-growth startups in underserved markets. Their portfolio includes companies such as Docspert Health, a telehealth company offering medical consultations by international medical experts to patients in Egypt and MENA, and Proteinea, which is pioneering the future of biologics to tackle life-threatening diseases. Sawari Ventures is committed to responsible investment, aiming to create value not only for their portfolio and investors but also for the wider ecosystem and societies in which they operate. They have established a tailored framework to effectively integrate ESG considerations into fund decision-making and are raising awareness and building capacity in ESG matters both at the fund and portfolio level. In the process, they are looking to establish Sawari Ventures as the go-to VC fund for ESG & Impact integration in the region.